EssilorLuxottica brought its Stellest 2.0 spectacle lens to 100% Optical (28 February – 2 March), highlighting the new design features and clinical trial findings for the myopia management lens.
The Stellest lens, which launched in 2020, features highly aspherical lenslet target (HALT) technology.
Charlotte Timbury, director of medical and professional affairs for north Europe at EssilorLuxottica, explained that Stellest 2.0 represents an evolution of the original design, now incorporating HALT Max technology.
With the new design, the mean power and asphericity across the lenslets has been increased to provide a stronger optical signal to slow down axial elongation.
Timbury said: “That is achieved by increasing the area of non-focused light and the positioning is slightly further away from the retina. That’s what helps us to give that stronger signal to the brain to slow down axial elongation.”
An extra ring of lenslets has been incorporated into the design, now with 12 rings instead of 11, and options for the diameter have been increased up to 75mm lens diameter.
As with the original Stellest, the lens is made from Airwear polycarbonate.
Timbury emphasised that “Stellest first generation is not going anywhere.”
EssilorLuxottica conducted a contralateral crossover clinical trial with the Stellest 2.0 in Singapore with 50 children.
“We compared the axial length growth between Stellest first generation and Stellest 2.0 and what we found at both six and 12-month markers was Stellest 2.0 was more effective at slowing down axial elongation,” Timbury explained.
She added: “So much so that the group wearing Stellest 2.0 had 1.88 times slower axial elongation than those wearing Stellest.”
From the clinical research and trials, EssilorLuxottica have found that the Stellest 2.0 with HALT Max technology could be a good solution for children who are younger, or who have a more rapid onset of myopia, as well as those who are already in a myopia management but are noting a progression every year or six months.
Comments (0)
You must be logged in to join the discussion. Log in